M135R is a novel cell surface virulence factor of myxoma virus

Journal of Virology

Volumn 81, Issue 1, 2007, Pages 106-114

  Barrett, John W ^a   Sypula, Joanna ^a   Wang, Fuan ^a   Alston, Lindsay R ^a   Shao, Zhuhong ^a   Gao, Xiujuan ^a   Irvine, Timothy S ^a   McFadden, Grant ^a  

^a ROBARTS RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; CELL SURFACE PROTEIN; M135R PROTEIN; VIRULENCE FACTOR; VIRUS DNA; VIRUS PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COWPOX VIRUS; ECTROMELIA VIRUS; EMBRYO; FIBROBLAST CULTURE; IMMUNOBLOTTING; IMMUNOPRECIPITATION; MONKEYPOX VIRUS; MYXOMA VIRUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RABBIT; SMALLPOX VIRUS; VACCINIA VIRUS; VIRUS INFECTION; VIRUS PATHOGENESIS; VIRUS RECOMBINANT; VIRUS VIRULENCE;

AMINO ACID SEQUENCE; ANIMALS; FLUORESCENT ANTIBODY TECHNIQUE; IMMUNOBLOTTING; MEMBRANE PROTEINS; MOLECULAR SEQUENCE DATA; MYXOMA VIRUS; MYXOMATOSIS, INFECTIOUS; RABBITS; RECEPTOR, INTERFERON ALPHA-BETA; SEQUENCE ALIGNMENT; VACCINIA VIRUS; VIRAL PROTEINS; VIRULENCE FACTORS; VIRUS REPLICATION;

MYXOMA VIRUS; ORYCTOLAGUS CUNICULUS; POXVIRIDAE; VACCINIA VIRUS;

EID: 33845762303     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.01633-06     Document Type: Article

References (36)

1. Alcami, A. 2003. Viral mimicry of cytokines, chemokines and their receptors. Nat. Rev. Immunol. 3:36-50.
2. Alcami, A., and S. Efstathiou. 2000. Soluble chemokine binding proteins are also encoded by herpesviruses. Immunol. Today 21:526-527.
3. Alcami, A., J. A. Symons, and G. L. Smith. 2000. The vaccinia virus soluble alpha/beta interferon (IFN) receptor binds to the cell surface and protects cells from the antiviral effects of IFN. J. Virol. 74:11230-11239.
4. Alcamí, A., and U. H. Koszinowski. 2000. Viral mechanisms of immune evasion. Immunol. Today 21:447-455.
5. Altin, J. G., and E. B. Pagler. 1995. A one-step procedure for biotinylation and chemical cross-linking of lymphocyte surface and intracellular membrane-associated molecules. Anal. Biochem. 224:382-389.
6. 5a. Animals for Research Act. 1971. Ontario public law, bill 194, Toronto, Ontario, Canada.
7. Barrett, J. W., J. X. Cao, S. Hota-Mitchell, and G. McFadden. 2001. Immunomodulatory proteins of myxoma virus. Semin. Immunol. 13:73-84.
8. 6a. Bradford, M. M. 1976. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72:248-254.
9. Brukman, A., and L. W. Enquist. 2006. Suppression of the interferon-mediated innate immune response by pseudorabies virus. J. Virol. 80:6345-6356.
10. Brunetti, C. R., M. Paulose-Murphy, R. Singh, J. Qin, J. W. Barrett, A. Tardivel, P. Schneider, K. Essani, and G. McFadden. 2003. A secreted high-affinity inhibitor of human TNF from Tanapox virus. Proc. Natl. Acad. Sci. USA 100:4831-4836.
11. Cameron, C., S. Hota-Mitchell, L. Chen, J. Barrett, J.-X. Cao, C. Macaulay, D. Wilier, D. Evans, and G. McFadden. 1999. The complete DNA sequence of myxoma virus. Virology 264:298-318.
12. 9a. Canadian Food Inspection Agency. 1996. Containment standards for veterinary facilities. Canadian Food Inspection Agency, Ottawa, Ontario, Canada.
13. Colamonici, O. R., P. Domanski, S. M. Sweitzer, A. Larner, and R. M. L. Buller. 1995. Vaccinia virus B18R gene encodes a type I interferon-binding protein that blocks interferon α transmembrane signaling. J. Biol. Chem. 270:15974-15978.
14. Fernandez-Sesma, A., S. Marukian, B. J. Ebersole, D. Kaminski, M. S. Park, T. Yuen, S. C. Sealfon, A. Garcia-Sastre, and T. M. Moran. 2006. Influenza virus evades innate and adaptive immunity via the NS1 protein. J. Virol. 80:6295-6304.
15. Garcia-Sastre, A., and C. A. Biron. 2006. Type 1 interferons and the virus-host relationship: a lesson in detente. Science 312:879-882.
16. Haga, I. R., and A. G. Bowie. 2005. Evasion of innate immunity by vaccinia virus. Parasitology 130(Suppl.):S11-S25.
17. 13a. Health Canada. 1996. Laboratory safety guidelines, 2nd ed. Health Canada, Ottawa, Ontario, Canada.
18. Johnston, J. B., and G. McFadden. 2003. Poxvirus immunomodulatory strategies: current perspectives. J. Virol. 77:6093-6100.
19. Johnston, J. B., and G. McFadden. 2004. Technical knockout: understanding poxvirus pathogenesis by selectively deleting viral immunomodulatory genes. Cell. Microbiol. 9:695-705.
20. Kerr, P., and G. McFadden. 2002. Immune responses to myxoma virus. Viral Immunol. 15:229-246.
21. Kotenko, S. V., G. Gallagher, V. V. Baurin, A. Lewis-Antes, M. Shen, N. K. Shah, J. A. Langer, F. Sheikh, H. Dickensheets, and R. P. Donnelly. 2003. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat. Immunol. 4:69-77.
22. Mossman, K., C. Upton, R. M. Buller, and G. McFadden. 1995. Species specificity of ectromelia virus and vaccinia virus interferon-gamma binding proteins. Virology 208:762-769.
23. 18a. Olfert, E. D., B. M. Cross, and A. A. McWilliam. 1993. Guide to the care and use of experimental animals, 2nd ed. Canadian Council on Animal Care, Ottawa, Ontario, Canada.
24. Opgenorth, A., K. Graham, N. Nation, D. Strayer, and G. McFadden. 1992. Deletion analysis of two tandemly arranged virulence genes in myxoma virus, M11L and myxoma growth factor. J. Virol. 66:4720-4731.
25. Opgenorth, A., D. Strayer, C. Upton, and G. McFadden. 1992. Deletion of the growth factor gene related to EGF and TGF α reduces virulence of malignant rabbit fibroma virus. Virology 186:175-191.
26. Rahman, M., and G. McFadden. 2006. Modulation of tumor necrosis factor (TNF) by microbioal pathogens. PLoS Pathogens 2:66-77.
27. Rahman, M. M., J. W. Barrett, P. Brouckaert, and G. McFadden. 2006. Variation in ligand binding specificities of a novel class of poxvirus-encoded TNF-binding protein. J. Biol. Chem. 281:22517-22526.
28. Schreiber, M., and G. McFadden. 1994. The myxoma virus TNF-receptor homologue (T2) inhibits tumor necrosis factor-alpha in a species-specific fashion. Virology 204:692-705.
29. Seet, B. T., J. B. Johnston, C. R. Brunetti, J. W. Barrett, H. Everett, C. Cameron, J. Sypula, S. H. Nazarian, A. Lucas, and G. McFadden. 2003. Poxviruses and immune evasion. Annu. Rev. Immunol. 21:377-423.
30. Symons, J. A., A. Alcamí, and G. L. Smith. 1995. Vaccinia virus encodes a soluble type I interferon receptor of novel structure and broad species specificity. Cell 81:551-560.
31. Ueda, Y., M. Ito, and I. Tagaya. 1969. A specific surface antigen induced by poxvirus. Virology 38:180-182.
32. Ueda, Y., I. Tagaya, H. Amano, and M. Ito. 1972. Studies on the early antigens induced by vaccinia virus. Virology 49:794-800.
33. Upton, C., K. Mossman, and G. McFadden. 1992. Encoding of a homolog of the IFN-gamma receptor by myxoma virus. Science 258:1369-1372.
34. van Horssen, R., T. L. Ten Hagen, and A. M. Eggermont. 2006. TNF-alpha in cancer treatment: molecular insights, antitumor effects, and clinical utility. Oncologist 11:397-408.
35. Wang, F., Y. Ma, J. W. Barrett, X. Gao, J. Loh, E. Barton, H. W. Virgin, and G. McFadden. 2004. Disruption of Erk-dependent type I interferon induction breaks the myxoma virus species barrier. Nat. Immunol. 5:1266-1274.
36. Willer, D. O., G. McFadden, and D. H. Evans. 1999. The complete genome sequence of shope (rabbit) fibroma virus. Virology 264:319-343.